Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Winston Kim who wrote (361)	5/21/1998 2:14:00 AM
From: Nikole Wollerstein	Respond to of 705

If we extrapolate data from mice, ENMD will need 2g of angiostatin/day/patient. You can reasonably get 20 g of protein from 1000 l fermenter in 2 days. To inject 2g off bacterially produce protein/day in humans and do not induce anafialactic shock it shouldd be purified at least to 99.9% purity. I think at this rate several month treatment will cost more than 100 000$(just prduction costs). The conclusion: unless ENMD will find out how this proteines work and find more active components they will have hard time produce enough protein even for clinical trials.